Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-PsA 1: upadacitinib versus placebo and adalimumab in active psoriatic arthritis
NL-OMON55411Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib and adalimumab in psoriatic arthritis (PsA) (4 arms), sponsored by AbbVie Inc. Primary endpoint: ACR20 response. Started Aug 2018; status: recruiting.
02
Drugs
upadacitinibadalimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON55411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55411.